Concomitant lucio phenomenon and erythema nodosum in a leprosy patient: clues for their distinct pathogeneses.
Lepromatous leprosy patients may develop necrotic lesions, usually in the context of Lucio phenomenon (LP) or severe erythema nodosum (EN). The clinical and histopathological characteristics of the necrotic manifestations of both entities may eventually be confounded. We describe a patient with lepromatous leprosy who developed, since the 4th month of her first pregnancy, recurrent necrotic lesions in lower limbs, which, at the postpartum, worsened and led to partial destruction of ears and nose. In addition, she referred painful nodes on upper limbs since 1 year before pregnancy and intermittent swelling and tenderness of the ankles, which together with a right tibial and ulnar neuritis led to the diagnosis of, erythema nodosum leprosum (ENL). The histopathology of a biopsy of the upper limb (ENL) revealed a dermal-hypodermal inflammation with vasculitis and vascular lumen narrowing, whereas biopsy of the lower limb (LP) revealed small vessels with fibrin thrombi on the superficial layer of the dermis without inflammatory infiltrate and no evidence of vasculitis. Thus, besides having several different clinical features, LP and ENL result from different pathogenetic mechanisms. The histopathological and clinical features distinguishing both entities are proposed. This distinction is important because decrease in bacillary load through multidrug therapy is the main target in LP, whereas in ENL, concomitant reduction of the reaction by means of thalidomide or high-dose steroids is recommended.
Benard
Gil
G
Division of Clinical Dermatology, Clinics Hospital, Medical School of the University of São Paulo, São Paulo, Brazil.
Sakai-Valente
Neusa Y
NY
Bianconcini Trindade
Maria Angela
MA
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001706:Biopsy; D004359:Drug Therapy, Combination; D004893:Erythema Nodosum / Q000382:microbiology / Q000473:pathology*; D005260:Female; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use; D015440:Leprosy, Lepromatous / Q000382:microbiology / Q000473:pathology*; D009166:Mycobacterium leprae / Q000302:isolation & purification / Q000472:pathogenicity; D009336:Necrosis; D011239:Prednisolone / Q000627:therapeutic use; D012867:Skin / Q000382:microbiology / Q000473:pathology*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D007917:Leprostatic Agents; D011239:Prednisolone